Evidence supporting the use of: Bacoside
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bacoside, a major active constituent of Bacopa monnieri (commonly known as Brahmi), has been studied in the context of neurodegenerative diseases, including Parkinson’s Disease (PD). The use of bacosides for PD is primarily justified by preclinical scientific research rather than traditional use. In animal models, bacosides have demonstrated neuroprotective effects, including antioxidative action, inhibition of neuronal apoptosis, and reduction of neuroinflammation. Studies in rodent models of PD—induced by neurotoxins such as 6-hydroxydopamine or MPTP—have shown that bacoside administration can attenuate motor deficits, preserve dopaminergic neurons in the substantia nigra, and reduce markers of oxidative stress and inflammation in the brain (e.g., Uabundit et al., 2014).

However, clinical trials in humans with Parkinson’s Disease are lacking, and the evidence is not sufficient to recommend bacoside as a treatment for PD. The current evidence comes from in vitro studies and animal models, which suggest a potential mechanism for neuroprotection but do not establish efficacy or safety in humans with PD. Thus, while bacosides are scientifically investigated for their neuroprotective properties, the overall evidence for their use in Parkinson’s Disease remains preliminary (rated 2/5).

In summary, bacoside’s use in PD is supported by early-stage scientific research, not by tradition or robust clinical evidence. More rigorous human studies are needed to confirm any therapeutic benefit in Parkinson’s Disease.

More about bacoside
More about Parkinson's Disease

Products containing bacoside

We currently have no products on Vitabase that contain this ingredient.